

October 26, 2012

Press Release

The Research Foundation for Microbial Diseases of Osaka University
Mitsubishi Tanabe Pharma Corporation

Launch of TETRABIK
Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain)
Combined Vaccine

The Research Foundation for Microbial Diseases of Osaka University (Headquarters: Suita, Osaka, Chairman, Board of Directors: Yasushi Higashi, hereafter; BIKEN) and Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, President and CEO: Michihiro Tsuchiya, hereafter; Mitsubishi Tanabe) announced today that they would launch on October 31, 2012 TETRABIK, Subcutaneous Injection Syringe [generic name: Adsorbed Diphtheria-purified Pertussis-Tetanus inactivated polio (Sabin strain) Combined vaccine; hereafter, this drug], a combined vaccine that prevents acute poliomyelitis (polio), pertussis, diphtheria and tetanus.

TETRABIK is a prophylactic injection comprising a *Bordetella pertussis* protective antigen, diphtheria toxoid, tetanus toxoid and inactivated Sabin types 1, 2 and 3 of polio virus as active ingredients, and is scheduled to be included in the periodical inoculation program on coming November 1.

Poliomyelitis, often called polio is an infectious disease with polio virus that mainly affects infants and young children. If the spinal cord is infected with the virus, even partially, paralysis may persist in the extremities. It is a disease against which the WHO is implementing enhanced measures for its eradication in cooperation with member countries. In 1964, Japan commenced a periodical inoculation program with a domestically produced live-attenuated polio vaccine. Since 1980, when the last patient in the country was reported, there has been no incidence of polio by wild-strain polio virus.

Since inoculation with live-attenuated oral polio vaccine very rarely results in paralytic symptoms similar to those in natural polio, however, there had been strong demand for switching to inactivated polio vaccine. Against this background, and taking into account reducing the vaccinee's burden from frequent inoculations in infancy, BIKEN had been working on developing a combined vaccine containing an inactivated polio vaccine developed by the Japan Polio Research Institute, and obtained marketing approval last July. From now on, TETRABIK will be manufactured by BIKEN and marketed by Mitsubishi Tanabe.

BIKEN and Mitsubishi Tanabe expect to contribute to needs in prophylactic practice for a broad range of infectious diseases and the health of people of the world through manufacturing and stably supplying vaccines and therapeutics.

Contact for Inquiries	
The Research Foundation for Microbial Diseases of Osaka University Administration Division Planning Department Phone: +81-875-25-4175	Mitsubishi Tanabe Pharma Corporation Corporate Communications Department Phone: +81-6-6205-5211